Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | FOS | P01100 | 2/20 | 0.47 |
| ▸ | JUN | P05412 | 2/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.47 |
| ▸ | RELA | Q04206 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5913955 | 0.87 | PDE4B (0.51) | RAB9AMAPK8JAK3TYRO3 | |
| SCHEMBL5316176 | 0.84 | PDE4B (0.44) | LMNAMAPK8GAATDP1JAK3 | |
| SCHEMBL5264072 | 0.80 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2MAPTLMNAMAPK1 | |
| SCHEMBL4183360 | 0.77 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2MAPTLMNAMAPK1 | |
| SCHEMBL11160276 | 0.75 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2MAPTLMNAMAPK1 | |
| SCHEMBL5089195 | 0.75 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2MAPTLMNAMAPK1 | |
| SCHEMBL7210767 | 0.74 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2MAPTLMNAMAPK1 | |
| SCHEMBL11158474 | 0.74 | ALDH1A1 (0.69) | ALDH1A1SMN1; SMN2MAPTLMNAMAPK1 | |
| SCHEMBL11283968 | 0.74 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2MAPTLMNAMAPK1 | |
| SCHEMBL11276702 | 0.74 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2MAPTLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794135-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-06-13 | — | — | EP | claimed |
| WO-2006037117-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-04-06 | — | — | WO | claimed |
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2006-03-30 | — | — | US | claimed |
| EP-1794135-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006037117-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | MAPT, MYLK2, IAPP | ALDH1A1 3019/4885SMN1; SMN2 11/4885MAPT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.